The ELIXA Trial: Lixisenatide's Cardiovascular Evidence
TRIAL-000016
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome, evaluated the cardiovascular safety of lixisenatide, the active ingredient in Adlyxin, in adults with type 2 diabetes who had experienced a recent acute coronary event. It enrolled 6,068 participants, making it one of the earlier dedicated cardiovascular outcomes trials in the GLP-1 class.
Key Results
ELIXA demonstrated that lixisenatide was cardiovascularly safe, non-inferior to placebo, but it did not show a statistically significant reduction in major cardiovascular events. This places ELIXA alongside EXSCEL as an example of a GLP-1 trial establishing safety without demonstrating the clearer benefit seen in later trials like LEADER, SUSTAIN-6, and SELECT.
Why This Result Pattern Matters
ELIXA's more neutral result is part of why cardiovascular benefit isn't treated as an automatic, guaranteed effect across every medication in the GLP-1 class. Differences in trial population, medication half-life, and dosing pattern (lixisenatide is a short-acting, once-daily, mealtime-dosed medication, unlike the longer-acting weekly medications in trials like LEADER and SELECT) may all play a role in why results vary across this drug class.
References
- Pfeffer MA et al., ELIXA Trial, NEJM 2015
- The Lancet: Cardiovascular Outcomes Across GLP-1 Receptor Agonist Trials (background on ELIXA population and comparative trial data)
Related Resources
Related Articles
How ELIXA Compares Across the GLP-1 Cardiovascular Trial Landscape
| Trial | Medication | Real Cardiovascular Result |
|---|---|---|
| ELIXA | Lixisenatide | Neutral, safe but no significant benefit |
| EXSCEL | Exenatide | Neutral, safe but no significant benefit |
| LEADER | Liraglutide | Significant real benefit shown |
| SUSTAIN-6 | Semaglutide | Significant real benefit shown |
| SELECT | Semaglutide | Significant real benefit, led to approval |
See DietApp's EXSCEL, LEADER, SUSTAIN-6, and SELECT trial pages for the full picture across this drug class. For lixisenatide's mechanism specifically, see DietApp's how lixisenatide works explainer.
Frequently Asked Questions
Why did lixisenatide not show cardiovascular benefit when other GLP-1s did? Real, possible factors include its shorter half-life, mealtime-only dosing, and differences in the specific trial population studied.
Is lixisenatide unsafe because of this neutral result? No, ELIXA confirmed real, genuine cardiovascular safety, non-inferior to placebo, it simply didn't demonstrate additional benefit.
Should this affect a decision to use Adlyxin? This is a real, individual medical decision worth discussing directly with your provider alongside your specific health profile.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
elixa-trial-lixisenatide